Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoli Mi

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The New England Journal of Medicine|October 11, 2023
Genetic Basis of Relapse after GPRC5D-Targeted CAR T CellsXiaoli Mi, Alex Penson, Omar Abdel-Wahab, et al.
JCO Precision Oncology|September 14, 2020
<i>FGFR1</i> Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute LeukemiaYing Liu, Xiaoli Mi, Ramya Gadde, et al.
Elife|November 24, 2018
Targets and genomic constraints of ectopic Dnmt3b expressionYingying Zhang, Jocelyn Charlton, Rahul Karnik, et al.
The Lancet. Haematology|August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trialJustin Taylor, Xiaoli Mi, Alexander V Penson, et al.
Blood|July 9, 2020
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasmsJustin Taylor, Xiaoli Mi, Khrystyna North, et al.
Leukemia|October 9, 2023
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trialJan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, et al.
American Journal of Hematology|August 18, 2018
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutationsXiaoli Mi, Gabriel Griffin, Winston Lee, et al.
Leukemia|January 24, 2025
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignanciesJan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, et al.
Cancer Immunology Research|July 3, 2024
Augmenting CAR T-cell Functions with LIGHTWinson Cai, Kento Tanaka, Xiaoli Mi, et al.
The Journal of Experimental Medicine|March 28, 2019
Impaired human hematopoiesis due to a cryptic intronic <i>GATA1</i> splicing mutationNour J Abdulhay, Claudia Fiorini, Jeffrey M Verboon, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The New England Journal of Medicine|October 11, 2023
Genetic Basis of Relapse after GPRC5D-Targeted CAR T CellsXiaoli Mi, Alex Penson, Omar Abdel-Wahab, et al.
JCO Precision Oncology|September 14, 2020
<i>FGFR1</i> Rearrangement Guides Diagnosis and Treatment of a Trilineage B, T, and Myeloid Mixed Phenotype Acute LeukemiaYing Liu, Xiaoli Mi, Ramya Gadde, et al.
Elife|November 24, 2018
Targets and genomic constraints of ectopic Dnmt3b expressionYingying Zhang, Jocelyn Charlton, Rahul Karnik, et al.
The Lancet. Haematology|August 1, 2020
Safety and activity of selinexor in patients with myelodysplastic syndromes or oligoblastic acute myeloid leukaemia refractory to hypomethylating agents: a single-centre, single-arm, phase 2 trialJustin Taylor, Xiaoli Mi, Alexander V Penson, et al.
Blood|July 9, 2020
Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasmsJustin Taylor, Xiaoli Mi, Khrystyna North, et al.
Leukemia|October 9, 2023
E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: a phase II clinical trialJan Philipp Bewersdorf, Maximilian Stahl, Justin Taylor, et al.
American Journal of Hematology|August 18, 2018
Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutationsXiaoli Mi, Gabriel Griffin, Winston Lee, et al.
Leukemia|January 24, 2025
Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignanciesJan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, et al.
Cancer Immunology Research|July 3, 2024
Augmenting CAR T-cell Functions with LIGHTWinson Cai, Kento Tanaka, Xiaoli Mi, et al.
The Journal of Experimental Medicine|March 28, 2019
Impaired human hematopoiesis due to a cryptic intronic <i>GATA1</i> splicing mutationNour J Abdulhay, Claudia Fiorini, Jeffrey M Verboon, et al.
Pageof 2